Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 34 n° 316

Posts Tagged ‘biopharma’

Propanc Biopharma Advances POP1 Drug Discovery Program

Posted by fidest press agency su giovedì, 21 novembre 2019

Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the POP1 research and drug discovery program has made significant advancements towards producing synthetic versions of the two proenzymes, trypsinogen and chymotrypsinogen. With the aim of producing large quantities of trypsinogen and chymotrypsinogen for commercial use, exhibiting minimal variation between lots and without sourcing the proenzymes from animals, the Company is undertaking a challenging research project in collaboration with the universities of Jaén and Granada, led by research scientist Mr. Aitor González, supported by Dr. Macarena Perán, Ph.D. and Dr. Julian Kenyon, M.D. as joint supervisors, representing the Universities and Propanc, respectively.
So far, the Company’s scientific researchers have developed a novel expression system. At the research laboratories at the universities of Jaén and Granada, scientific researchers are in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen with this expression system. After western blotting analysis of cell extracts, they observed the cells are producing the proteins, and further sequence analysis will be completed in order to confirm the correct sequence of both proenzymes produced.
One specific objective of the project will be to synthesize by an in vivo system both proenzymes to produce crystalized proteins that could be maintained for long periods without suffering degradation, even in absence of refrigeration. This will be particularly useful for a longer shelf life as well as global distribution of the drug product, particularly in warmer climates and developing regions where refrigeration may not be available.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Loncar China BioPharma ETF (CHNA) Celebrates One-Year Anniversary

Posted by fidest press agency su domenica, 18 agosto 2019

Biopharma is a focus of China as it seeks to shift its economy toward innovation and become a global leader in world-class science and medicine. China has a large pool of talent in life sciences, has harmonized its drug regulatory agency with international standards and is adding innovative drugs to its national reimbursement list at an expedited pace.
The CHNA ETF launched in an effort to get ahead of this trend and aims to help investors capture leaders in the space through the convenience of one security that trades in the United States. It is based on the Loncar China BioPharma Index, which was developed by biotechnology investor and Loncar Investments CEO Brad Loncar.“China’s future is rooted in innovation,” says Loncar. “We believe investing in medicine and the scientific revolution within China is a compelling way to harness and capitalize on China’s new and growing economy. The country’s commitment to life sciences and its ability to be a major player in the industry is of global significance and this has been reinforced by the progress seen over the last year.” A new rule implemented by the Hong Kong Stock Exchange allows pre-revenue biotech companies to list publicly for the first time. With this in mind, the CHNA ETF held its most recent semi-annual rebalance on Aug. 12 and added three companies that recently had initial public offerings in Hong Kong to the fund: CanSino Biologics (HKEX: 6185), Hansoh Pharmaceutical Group (HKEX: 3692) and Viva Biotech (HKEX: 1873). This now makes a total of six life sciences companies held by CHNA that are newly listed in Hong Kong over the last year. Click here to see all holdings of the CHNA ETF.For more information and to read Brad Loncar’s commentary, CEO interviews and other exclusive research, please visit Visitors can sign up to receive email alerts at the bottom of any webpage.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

LC GC® and BioPharm International Present Webcast on Glycan Analysis

Posted by fidest press agency su domenica, 14 luglio 2019

LC GC®, a leading multimedia platform of peer-reviewed technical information on the field of chromatography and the separation sciences, and BioPharm International®, a digital resource of technical articles, technology reports, regulatory and business columns, and expert commentary surrounding biopharmaceuticals, biotechnology and bioprocessing, will host the webcast, “Improving Confidence and Productivity in Released Glycan Analysis for Biotherapeutic Development,” on Wednesday, July 17, at 11 a.m. EDT.“This webcast is part two of a three-part series introducing the Waters BioAccord LC-MS System, the first SmartMSTM-Enabled Biopharma Solution,” said Tom Ehardt, president of MultiMedia Healthcare, LLC. “We look forward to hosting this informational webcast with Waters software expert, Dr. Zhang.”Senior scientist in the Biopharmaceutical Group of Scientific Operations at Waters Corporation, Ximo Zhang, PhD, will discuss workflows developed on the compact and integrated LC-MS System, how to improve productivity and reproducibility with automated sample preparation and present case studies demonstrating how simplified analytical workflow transforms high-quality LC/FLR/MS data into meaningful results for released N-glycan analysis.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Propanc Biopharma to Present at the 2019 BIO CEO & Investor Conference

Posted by fidest press agency su giovedì, 31 gennaio 2019

Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc”), a clinical stage biopharmaceutical company focused on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that its Chief Executive Officer, James Nathanielsz, will be presenting at the 2019 BIO CEO & Investor Conference on Tuesday, February 12, 2019, at 9:45 am EST. The conference will be held at the New York Marriott Marquis.“The BIO CEO & Investor Conference is one of the largest investor conferences, focused on established and emerging publicly traded and select private biotech companies, and I am honored to be selected to present at this year’s conference. As we prepare to transition our lead technology into human trials, this is a great opportunity for us to meet with investors and potential partners to provide a company update for 2019, focusing on the advancement of our lead product, PRP,” said James Nathanielsz, CEO and Executive Chairman of Propanc. “PRP is a solution for intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen. Progressing towards a first-in-human study, PRP seeks to prevent recurrence and metastasis from solid tumors by targeting and eradicating cancer stem cells.”Investors and potential partners attending the conference who wish to meet with Propanc’s management can reach out through the BIO One-on-One Partnering system to request a meeting. For those not planning to attend the meeting, please contact Lisa DeScenza to set up a call with Mr. Nathanielsz to learn more about Propanc.A live audio webcast of Mr. Nathanielsz’s presentation will be accessible within the Investor Relations section of Propanc’s website at An archived version of this webcast will be available for 90 days following the conclusion of the live presentation.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »